Literature DB >> 9565129

Effective treatment of lymphedema of the extremities.

D S Ko1, R Lerner, G Klose, A B Cosimi.   

Abstract

OBJECTIVE: To define the immediate and long-term volumetric reduction following complete decongestive physiotherapy (CDP) for lymphedema.
DESIGN: Prospective study of consecutively treated patients.
SETTING: Freestanding outpatient referral centers. PATIENTS: Two hundred ninety-nine patients referred for evaluation of lymphedema of the upper (2% primary, 98% secondary) or lower (61.3% primary, 38.7% secondary) extremities were treated with CDP for an average duration of 15.7 days. Lymphedema reduction was measured following completion of treatment and at 6- and 12-month follow-up visits. INTERVENTION: Complete decongestive physiotherapy is a 2-phase noninvasive therapeutic regimen. The first phase consists of manual lymphatic massage, multilayered inelastic compression bandaging, remedial exercises, and meticulous skin care. Phase 2 focuses on self-care by means of daytime elastic sleeve or stocking compression, nocturnal wrapping, and continued exercises. MAIN OUTCOME MEASURES: Average limb volumes in milliliters were calculated prior to treatment, at the end of phase 1, and at 6- to 12-month intervals during phase 2 to assess percent volume reduction.
RESULTS: Lymphedema reduction averaged 59.1% after upper-extremity CDP and 67.7% after lower-extremity treatment. With an average follow-up of 9 months, this improvement was maintained in compliant patients (86%) at 90% of the initial reduction for upper extremities and lower extremities. Noncompliant patients lost a part (33%) of their initial reduction. The incidence of infections decreased from 1.10 infections per patient per year to 0.65 infections per patient per year after a complete course of CDP.
CONCLUSIONS: Complete decongestive physiotherapy is a highly effective treatment for both primary and secondary lymphedema. The initial reductions in volume achieved are maintained in the majority of the treated patients. These patients typically report a significant recovery from their previous cosmetic and functional impairments, and also from the psychosocial limitations they experienced from a physical stigma they felt was often trivialized by the medical and payor communities.

Entities:  

Mesh:

Year:  1998        PMID: 9565129     DOI: 10.1001/archsurg.133.4.452

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  53 in total

1.  An integrated therapy concept for reduction of postoperative complications after resection of a panniculus morbidus.

Authors:  Georgios Koulaxouzidis; Sebastian M Goerke; Steffen U Eisenhardt; Florian Lampert; G Bjoern Stark; Etelka Foeldi; Nestor Torio-Padron
Journal:  Obes Surg       Date:  2012-04       Impact factor: 4.129

2.  Can ICF model for patients with breast-cancer-related lymphedema predict quality of life?

Authors:  Jau-Yih Tsauo; Hsiu-Chuan Hung; Han-Ju Tsai; Chiun-Sheng Huang
Journal:  Support Care Cancer       Date:  2010-04-06       Impact factor: 3.603

3.  Near-infrared fluorescence imaging of lymphatics in head and neck lymphedema.

Authors:  Erik A Maus; I-Chih Tan; John C Rasmussen; Milton V Marshall; Caroline E Fife; Latisha A Smith; Renie Guilliod; Eva M Sevick-Muraca
Journal:  Head Neck       Date:  2010-11-12       Impact factor: 3.147

4.  A prospective randomised study of alginate-drenched low stretch bandages as an alternative to conventional lymphologic compression bandaging.

Authors:  Renato G Kasseroller; Erich Brenner
Journal:  Support Care Cancer       Date:  2009-05-31       Impact factor: 3.603

5.  A 61-year-old woman with chronic leg lymphedema managed with complete decongestive therapy.

Authors:  Larysa Bondalevich; Stefan de Laplante
Journal:  CMAJ       Date:  2020-06-29       Impact factor: 8.262

6.  Recent advances in medical treatment for lymphedema.

Authors:  Yoshihiro Ogawa
Journal:  Ann Vasc Dis       Date:  2012

7.  Therapeutic effects of hyaluronidase on acquired lymphedema using a newly developed mouse limb model.

Authors:  Kangsan Roh; Sungrae Cho; Jae-Hyun Park; Byong Chul Yoo; Won-Ki Kim; Seok-Ki Kim; Kyewon Park; Hee Kang; Jin-Mo Ku; Chang-Hwan Yeom; Kyunghoon Lee; Sukchan Lee
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-16

8.  Aqua lymphatic therapy in women who suffer from breast cancer treatment-related lymphedema: a randomized controlled study.

Authors:  Dorit Tidhar; Michal Katz-Leurer
Journal:  Support Care Cancer       Date:  2009-06-03       Impact factor: 3.603

9.  Clinical outcomes of extracorporeal shock wave therapy in patients with secondary lymphedema: a pilot study.

Authors:  Hasuk Bae; Ho Jeong Kim
Journal:  Ann Rehabil Med       Date:  2013-04-30

10.  Effectiveness of the treatment-phase of two-phase complex decongestive physiotherapy for the treatment of extremity lymphedema.

Authors:  Ritsu Yamamoto; Terumi Yamamoto
Journal:  Int J Clin Oncol       Date:  2007-12-21       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.